(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. by Jie Liu (15128)

Microalbuminuria and its Prognostic Significance in Patients with Acute Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction by Ömer Doğan Alataş (12698849)

“…Therefore, we aimed to investigate the frequency and prognostic value of microalbuminuria in patients hospitalized for acute heart failure (AHF) with preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmrEF), and reduced ejection fraction (HFrEF). …”

Changes in study endpoints in FAS analysis. by Masashi Sakuma (3923087)

Subjects:

Changes in maximal strength within each group after treatment. by Sergio R. Thomaz (20308465)

Subjects:

Species richness decreases significantly with increasing percent disturbance. by Catherine L. Cardelús (6429320)

Serial changes of urinary 8-OHdG, L-FABP, osmolality and creatinine levels at weeks 12 and 24. by Masashi Sakuma (3923087)

Subjects:

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction by Hannah A. Blair (6846307)

“…<br></p><p><br></p><p></p><p><b>Abstract </b>Dapagliflozin [Farxiga^® (USA); Forxiga^®(EU)], a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV disease. …”

Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction by Connie Kang (7248215)

“…<br> </p> <p><br></p> <p>Abstract</p> <p>Vericiguat (Verquvo^®) is the first oral soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of adults with symptomatic, chronic heart failure with reduced ejection fraction (HFrEF). In the phase III VICTORIA trial, vericiguat added to standard of care (SOC) was associated with a significantly lower risk of the primary composite endpoint of death from cardiovascular (CV) causes or first hospitalization from heart failure (HHF) than placebo added to SOC in adults with chronic HFrEF. …”

Cost-of-illness of heart failure with preserved and reduced ejection fraction in the Philippines by John Añonuevo (20494293)

“…</p> <p>The study utilized a bottom-up micro-costing approach to determine the economic burden of heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) across all NYHA classifications using a societal perspective. …”

Total tau levels are significantly decreased in the healthy older brains compared to the younger brains. by Shreyasi Chatterjee (3531506)

Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

Changes in urinary 8-OHdG, L-FABP and creatinine levels in each HFrEF and HFpEF patients (FAS). by Masashi Sakuma (3923087)

Subjects:

Changes in NT-proBNP, LVEF, E/e’ (FAS), and TRPG (PPS) in each HFrEF and HFpEF patients. by Masashi Sakuma (3923087)

Subjects:

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Image 2_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 1_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Table 2_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.docx by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 4_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Table 1_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.docx by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 5_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”